Trial Outcomes & Findings for A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 (NCT NCT00853580)
NCT ID: NCT00853580
Last Updated: 2018-03-12
Results Overview
A computerized test of visuospatial learning. Participants had to remember patterns associated with different locations on the screen, and during the test phase, as each pattern is presented, point to the appropriate location. The test starts at a very simple level and gradually increases in difficulty. Higher number of errors indicates poorer performance. Scale does not have a maximum range.
COMPLETED
PHASE2
146 participants
Baseline and Post-treatment (16 weeks)
2018-03-12
Participant Flow
Participants were recruited between July 2009 and May 2014 from 11 specialist NF1 academic clinics affiliated with the NF Clinical Trials Consortium.
After obtaining consent, participants were screened for study inclusion. If entry criteria were passed, they were randomized to study. All randomized participants were included in the primary efficacy analysis (baseline-to-post treatment) if they completed the baseline assessments.
Participant milestones
| Measure |
Lovastatin
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
Look alike placebo pill with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Overall Study
STARTED
|
74
|
72
|
|
Overall Study
COMPLETED
|
67
|
56
|
|
Overall Study
NOT COMPLETED
|
7
|
16
|
Reasons for withdrawal
| Measure |
Lovastatin
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
Look alike placebo pill with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
3
|
5
|
|
Overall Study
Protocol Violation
|
2
|
1
|
|
Overall Study
Withdrawal by Subject
|
2
|
8
|
|
Overall Study
Commenced contraindicated therapy
|
0
|
2
|
Baseline Characteristics
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Baseline characteristics by cohort
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=70 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
Total
n=144 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
74 Participants
n=99 Participants
|
70 Participants
n=107 Participants
|
144 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Continuous
|
11.5 Years
STANDARD_DEVIATION 2.25 • n=99 Participants
|
11.7 Years
STANDARD_DEVIATION 1.95 • n=107 Participants
|
11.6 Years
STANDARD_DEVIATION 2.10 • n=206 Participants
|
|
Sex: Female, Male
Female
|
31 Participants
n=99 Participants
|
27 Participants
n=107 Participants
|
58 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
43 Participants
n=99 Participants
|
43 Participants
n=107 Participants
|
86 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
6 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
61 Participants
n=99 Participants
|
54 Participants
n=107 Participants
|
115 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
7 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
12 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
57 participants
n=99 Participants
|
55 participants
n=107 Participants
|
112 participants
n=206 Participants
|
|
Region of Enrollment
Australia
|
17 participants
n=99 Participants
|
17 participants
n=107 Participants
|
34 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerized test of visuospatial learning. Participants had to remember patterns associated with different locations on the screen, and during the test phase, as each pattern is presented, point to the appropriate location. The test starts at a very simple level and gradually increases in difficulty. Higher number of errors indicates poorer performance. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=68 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery).
Baseline
|
15.8 PAL Total Errors
Standard Error 22.4
|
17.0 PAL Total Errors
Standard Error 15.4
|
|
Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery).
Post-treatment
|
10.3 PAL Total Errors
Standard Error 8.4
|
11.7 PAL Total Errors
Standard Error 11.7
|
PRIMARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Score! is a measure of sustained attention. Participants were required to silently count a series of aurally presented tones and say the total number of tones counted at the end of each trial. The number of tones ranged from 9 to 15, with a total of 10 trials (range 0-10). Higher values represent better performance.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Score! (Test of Everyday Attention for Children)
Baseline
|
6.0 Units on a scale
Standard Deviation 2.0
|
5.7 Units on a scale
Standard Deviation 2.4
|
|
Score! (Test of Everyday Attention for Children)
Post-treatment
|
7.3 Units on a scale
Standard Deviation 2.1
|
6.8 Units on a scale
Standard Deviation 2.5
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerized measure of spatial working memory. This task assessed the participant's ability to retain spatial information and to manipulate remembered items in working memory. In this test, participants were shown an array of boxes on a computer screen and they were required to search through the boxes for hidden tokens. One box at a time was touched until a blue token was found inside. Participants then commenced a new search for the next token. The key instruction was that, once a token had been located, that box would not be used again to hide another token. Unit of measure was between search errors, determined by the number of boxes a participant reopens in which a token had previously been found. Higher score indicated poorer performance. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=72 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=68 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Spatial Working Memory (Cambridge Neuropsychological Test Automated Battery)
Baseline
|
47.0 Errors
Standard Deviation 15.9
|
47.9 Errors
Standard Deviation 16.2
|
|
Spatial Working Memory (Cambridge Neuropsychological Test Automated Battery)
Post-treatment
|
40.4 Errors
Standard Deviation 17.2
|
41.6 Errors
Standard Deviation 17.0
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerized measure of spatial planning based on the "Tower of London" test. It required participants to move balls in a lower display to match a pattern shown in the upper display in a certain number of moves. More specifically, the participant was shown two displays containing three coloured balls. The displays were presented in such a way that they could be perceived as stacks of coloured balls held in socks suspended from a beam. The test administrator first demonstrated to the participant how to move the balls in the lower display to copy the pattern in the upper display and completed one demonstration problem, where the solution required one move. The participant then completed problems that increased in difficulty, from one through to five move problems. The unit of measure was the mean number of moves taken to complete a problem that could not be completed in less than five moves. The higher the score, the poorer the performance (range 5-12).
Outcome measures
| Measure |
Lovastatin
n=71 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Stockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).
Post-treatment
|
7.3 Moves
Standard Deviation 1.4
|
7.9 Moves
Standard Deviation 1.4
|
|
Stockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).
Baseline
|
7.9 Moves
Standard Deviation 1.4
|
8.0 Moves
Standard Deviation 1.3
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerized measure of inhibitory control. The participant quickly responded to an arrow stimulus by pressing one of two buttons (left or right), depending on the direction in which the arrow pointed on the screen. If an audio tone is present, the subject was supposed to withhold the response. The difficulty of the task was manipulated by altering the delay before a stop signal (auditory tone) was presented, known as the stop signal delay. The outcome from this measure was stop signal reaction time (last half of test), which was computed by subtracting the mean stop signal delay at which the participant was able to stop on 50% of trials from the mean reaction time on go trials. Poorer response inhibition was reflected by a larger stop signal reaction time. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=70 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Stop Signal Task (Cambridge Neuropsychological Test Automated Battery)
Post-treatment
|
227.2 Milliseconds
Standard Deviation 87.2
|
227.0 Milliseconds
Standard Deviation 93.7
|
|
Stop Signal Task (Cambridge Neuropsychological Test Automated Battery)
Baseline
|
264.7 Milliseconds
Standard Deviation 98.7
|
237.2 Milliseconds
Standard Deviation 75.9
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Sky Search is a measure of selective visual attention. Participants were presented with a A3 sheet with target stimuli (spaceships in identical pairs) randomly distributed among many distractors (spaceships in non-identical pairs). They were required to circle as many of the targets as possible as quickly as possible. The outcome measure (attention score), was a timing score reflecting the average time taken per target found. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Sky Search (Test of Everyday Attention for Children)
Baseline
|
4.4 Scores on a scale
Standard Deviation 1.7
|
5.0 Scores on a scale
Standard Deviation 2.1
|
|
Sky Search (Test of Everyday Attention for Children)
Post-treatment
|
4.0 Scores on a scale
Standard Deviation 2.0
|
4.4 Scores on a scale
Standard Deviation 2.1
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Sky Search DT is a test of divided attention. Children completed a parallel version of the Sky Search subtest while at the same time, silently counted the number of tones in a similar way to the Score! subtest. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Sky Search DT (Test of Everyday Attention for Children)
Baseline
|
9.9 Scores on a scale
Standard Deviation 15.5
|
9.6 Scores on a scale
Standard Deviation 18.6
|
|
Sky Search DT (Test of Everyday Attention for Children)
Post-treatment
|
7.0 Scores on a scale
Standard Deviation 15.6
|
6.6 Scores on a scale
Standard Deviation 11.6
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Creature Counting is a measure of attentional control. Participants were required to count "creatures" from top of the page to the bottom, using arrows as cues to switch from counting up to counting down (and vice versa). There were seven testing trials. The outcome variable was the total number of correct trials (range 0-7). Higher scores represent better performances.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Creature Counting (Test of Everyday Attention for Children)
Baseline
|
4.0 Scores on a scale
Standard Deviation 2.2
|
3.8 Scores on a scale
Standard Deviation 2.3
|
|
Creature Counting (Test of Everyday Attention for Children)
Post-treatment
|
4.5 Scores on a scale
Standard Deviation 1.9
|
4.6 Scores on a scale
Standard Deviation 1.8
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerised measure of impulse control. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Commission errors represented the number of times a participant incorrectly responded to the non-target (letter 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=64 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Commission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)
Post-treatment
|
58.8 T score
Standard Deviation 16.6
|
64.1 T score
Standard Deviation 18.4
|
|
Commission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)
Baseline
|
57.5 T score
Standard Deviation 12.4
|
62.1 T score
Standard Deviation 17.2
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A computerised measure of vigilance and concentration. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Omission errors represented the number of times a participant fails to respond to target letters (all other than 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=64 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Omission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)
Post-treatment
|
54.2 T score
Standard Deviation 10.5
|
55.5 T score
Standard Deviation 7.4
|
|
Omission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)
Baseline
|
54.7 T score
Standard Deviation 10.5
|
56.9 T score
Standard Deviation 6.9
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Parent rated inattentive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition. T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
ADHD Inattentive Scale, Conners ADHD Scales
Baseline
|
66.2 T score
Standard Deviation 12.6
|
64.0 T score
Standard Deviation 14.6
|
|
ADHD Inattentive Scale, Conners ADHD Scales
Post-treatment
|
59.5 T score
Standard Deviation 13.2
|
61.1 T score
Standard Deviation 13.3
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (16 weeks)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Parent rated hyperactive/impulsive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition.T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
ADHD Hyperactive/Impulsive Scale, Conners ADHD Scales
Baseline
|
65.5 T score
Standard Deviation 14.2
|
62.9 T score
Standard Deviation 15.6
|
|
ADHD Hyperactive/Impulsive Scale, Conners ADHD Scales
Post-treatment
|
62.3 T score
Standard Deviation 15.4
|
62.3 T score
Standard Deviation 16.7
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A measure of verbal fluency. Participants were required to spontaneously produce as many words as they could, beginning with a designated letter in 60 seconds. Three letters were used. Higher scores represent better performances. Raw data are reported summing total words generated for all three letters. Scale does not have a maximum range.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Controlled Oral Word Association Test
Baseline
|
22.2 Total words
Standard Deviation 8.9
|
21.2 Total words
Standard Deviation 8.6
|
|
Controlled Oral Word Association Test
Post-treatment
|
22.2 Total words
Standard Deviation 9.1
|
22.6 Total words
Standard Deviation 8.9
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A test of visuospatial judgement. The test measured the participant's ability to match the angle and orientation of lines in space. There were 30 trial in total. Correct response in a trial was awarded one point (range 0-30). Higher scores represent better performances. Raw data are reported.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=65 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Judgement of Line Orientation Test
Baseline
|
15.0 Total correct responses
Standard Deviation 6.6
|
14.6 Total correct responses
Standard Deviation 5.7
|
|
Judgement of Line Orientation Test
Post-treatment
|
17.2 Total correct responses
Standard Deviation 7.0
|
16.7 Total correct responses
Standard Deviation 6.4
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A parent-rated questionnaire of executive behaviour assessing behavioral regulation (inhibit, shift, emotional control) and metacognition (initiate, working memory, plan/organize, organization of materials, self-monitoring). T-scores for the Global Executive Composite (overall summary score) are reported. Higher scores indicate poorer executive behaviors.
Outcome measures
| Measure |
Lovastatin
n=72 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=65 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Behavior Rating Inventory of Executive Function Global Executive Composite
Baseline
|
63.5 T score
Standard Deviation 11.5
|
61.4 T score
Standard Deviation 11.9
|
|
Behavior Rating Inventory of Executive Function Global Executive Composite
Post-treatment
|
59.2 T score
Standard Deviation 13.2
|
58.8 T score
Standard Deviation 12.5
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A measure of visuoperceptual organization. Participants were required to rebuild an item puzzle based on disassembled pieces. Age scaled scores are reported, which have a population mean of 10 and standard deviation of 3 (range 1-19). Higher scores indicate better performances.
Outcome measures
| Measure |
Lovastatin
n=74 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=66 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Object Assembly (WISC-III)
Baseline
|
6.6 Scores on a scale
Standard Deviation 3.1
|
6.9 Scores on a scale
Standard Deviation 3.0
|
|
Object Assembly (WISC-III)
Post-treatment
|
7.8 Scores on a scale
Standard Deviation 3.6
|
7.5 Scores on a scale
Standard Deviation 3.3
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A parent-reported questionnaire assessing internalizing behaviors of anxiety, depression and somatization. T-scores are reported. Higher scores indicate increased internalizing behaviors. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=63 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Internalizing Behaviors, Behavior Assessment System for Children Second Edition
Baseline
|
55.2 T score
Standard Deviation 12.6
|
53.8 T score
Standard Deviation 11.8
|
|
Internalizing Behaviors, Behavior Assessment System for Children Second Edition
Post-treatment
|
52.6 T score
Standard Deviation 12.6
|
52.5 T score
Standard Deviation 11.4
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
A self-reported questionnaire assessing internalizing behaviors such as anxiety and depression. T-scores are reported. Higher scores indicate increased internalizing behaviors. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Outcome measures
| Measure |
Lovastatin
n=73 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=63 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Internalizing Behaviors, Behavior Assessment System for Children Second Edition
Baseline
|
50.9 T score
Standard Deviation 10.2
|
51.2 T score
Standard Deviation 8.7
|
|
Internalizing Behaviors, Behavior Assessment System for Children Second Edition
Post-treatment
|
47.9 T score
Standard Deviation 10.0
|
49.2 T score
Standard Deviation 8.5
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Parent-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate increased increased quality of life (range 0-100).
Outcome measures
| Measure |
Lovastatin
n=72 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=63 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Quality of Life Pediatric Quality of Life Inventory (PedsQL)
Baseline
|
62.8 Scores on a scale
Standard Deviation 15.7
|
64.6 Scores on a scale
Standard Deviation 18.1
|
|
Quality of Life Pediatric Quality of Life Inventory (PedsQL)
Post-treatment
|
69.2 Scores on a scale
Standard Deviation 16.0
|
68.1 Scores on a scale
Standard Deviation 16.6
|
SECONDARY outcome
Timeframe: Baseline and Post-treatment (week 16)Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).
Self-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate higher quality of life (range 0-100).
Outcome measures
| Measure |
Lovastatin
n=70 Participants
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=64 Participants
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
Psychosocial Quality of Life PedsQL
Baseline
|
67.2 Scores on a scale
Standard Deviation 17.0
|
70.0 Scores on a scale
Standard Deviation 18.1
|
|
Psychosocial Quality of Life PedsQL
Post-treatment
|
62.6 Scores on a scale
Standard Deviation 16.0
|
67.3 Scores on a scale
Standard Deviation 17.0
|
Adverse Events
Lovastatin
Placebo
Serious adverse events
| Measure |
Lovastatin
n=74 participants at risk
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=70 participants at risk
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
General disorders
Serious Adverse Event
|
1.4%
1/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
0.00%
0/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Blood and lymphatic system disorders
Serious Adverse Event
|
2.7%
2/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
0.00%
0/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Hepatobiliary disorders
Serious Adverse Event
|
2.7%
2/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
0.00%
0/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Musculoskeletal and connective tissue disorders
Serious Adverse Event
|
1.4%
1/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
0.00%
0/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Nervous system disorders
Serious Adverse Event
|
0.00%
0/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
1.4%
1/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
Other adverse events
| Measure |
Lovastatin
n=74 participants at risk
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
|
Placebo
n=70 participants at risk
Look alike placebo capsule with same dosing schedule as active lovastatin.
|
|---|---|---|
|
General disorders
General
|
39.2%
29/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
32.9%
23/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Cardiac disorders
Cardiovascular
|
9.5%
7/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
10.0%
7/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Gastrointestinal disorders
Gastrointestinal
|
44.6%
33/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
45.7%
32/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Blood and lymphatic system disorders
Hematologic
|
13.5%
10/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
17.1%
12/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Hepatobiliary disorders
Hepatobiliary
|
4.1%
3/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
5.7%
4/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal
|
28.4%
21/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
24.3%
17/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Nervous system disorders
Nervous
|
25.7%
19/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
37.1%
26/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory
|
43.2%
32/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
37.1%
26/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Skin and subcutaneous tissue disorders
Skin/appendages
|
28.4%
21/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
20.0%
14/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Eye disorders
Special senses - Eye
|
8.1%
6/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
4.3%
3/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
|
Ear and labyrinth disorders
Special Senses - Ear
|
8.1%
6/74 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
4.3%
3/70 • Baseline to Follow-up assessment (24 weeks)
Baseline to Follow-up assessment (24 weeks). Adverse events and serious adverse events were reported by organ system class.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place